Collegium Pharmaceutical, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Collegium Pharmaceutical, Inc. has issued its proxy statement for the 2026 Annual Meeting of Shareholders, detailing director nominations, executive compensation, and accounting firm ratification.
NASDAQ
Collegium Pharmaceutical will hold its annual shareholder meeting virtually on May 15, 2025, to vote on director elections, executive compensation, and other proposals.
NASDAQ
DEF 14A: Collegium Pharmaceutical Aims for Growth in 2025 with New Equity Incentive Plan and Board Changes
Collegium Pharmaceutical's proxy statement highlights a transformational year in 2024, marked by strategic acquisitions, financial achievements, and a forward-looking approach to growth and shareholder value.
NASDAQ
Collegium Pharmaceutical announces the withdrawal of Joseph Ciaffoni as a director nominee due to his upcoming departure as CEO, leading to a reduction in the board size.
NASDAQ
Collegium Pharmaceutical will hold its annual shareholder meeting virtually on May 16, 2024, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
Collegium Pharmaceutical achieved record net product revenue and adjusted EBITDA in 2023, increased its cash position, and executed its capital deployment strategy, including share repurchases.